Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2619760 | 0.89 | KDM4E (0.35) | SCN9AFPR2OPRM1KDM4EHTT | |
| SCHEMBL10249849 | 0.82 | — | — | |
| SCHEMBL2107102 | 0.82 | KDM4E (0.35) | KDM4EHTTATM | |
| SCHEMBL2107099 | 0.82 | KDM4E (0.35) | KDM4EHTTATM | |
| SCHEMBL2619761 | 0.81 | OPRM1 (0.33) | SCN9AOPRM1 | |
| SCHEMBL10251424 | 0.79 | — | — | |
| SCHEMBL10249862 | 0.76 | — | — | |
| SCHEMBL2106620 | 0.74 | NR1I2 (0.34) | — | |
| SCHEMBL2104522 | 0.74 | NR1I2 (0.34) | — | |
| SCHEMBL14641410 | 0.71 | NR1I2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120164103-A1 | Compounds and Methods for the Treatment or Prevention of Flavivirus Infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120164103-A1 | Compounds and Methods for the Treatment or Prevention of Flavivirus Infections | ZC3HAV1, YBX1, HAX1 | SCN9A 1755/4885FPR2 1467/4885OPRM1 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.